Blue Earth Diagnostics, one of the Bracco family of companies, is a recognized global industry leader in the development and commercialization of innovative, precision imaging radiopharmaceuticals that help to diagnose, stage and monitor cancer for patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, with a demonstrated track record in the rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals with a consistent commitment to providing service to its customers. Blue Earth Diagnostics’ products include a world-class franchise of PET diagnostic imaging agents for prostate cancer and an expanding pipeline portfolio that spans a variety of disease states, including neuro-oncology and multiple solid tumors. For more information, please visit: blueearthdiagnostics.com and prostatecancer-blueearthdx.com.